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The synthetic peptide, SFLLRNPNDKYEPF, has been recently described as a peptide mimicking the new amino-terminus created by cleavage 
of the thrombin receptor, therefore acting as an agonist of the thrombin receptor. This peptide was a porect mitogen for rdbbit arterial smooth 
muscle -ells (SMC) and exhibited the same activity as that of native a-thrombin. Both compounds stimulated the proliferation of growth-arrested 
SMCs with half-maximum itogenic responses at I nM. NAPAP. a synthetic inhibitor of the enzymatic activity of thrombin, specifically inhibitad 
thrombin-induced SMC growth (I& = 0.35 + 0.04pM) but was without effect on the mitogenic effect of the agonist peptide. These results therefore 
demonstrate that the mitogenic effect of a-thrombin for SMCs is intimately linked to its esterolytic activity. Heparin, which inhibited fetal calf 
serum-induced SMC growth, was without effect or. thrombin-induced SMC growth but strongly reduced the mitogenic effect of the agonist peptide 
(ICS = 32 5 5 rf@ml). This effect wa:: not relatd to the anti-coagulant activity of heparin but was highly dependent on molecular mass and on 
the global charge of the molecule and WGE alsc observed for other sulphated polysaccharides such as pentosan polysulphate. 
Thrambin: Vascular smooth muscle cell; Mitogen 
1. INTRODUCTION 
Over the past several years, a series of observations 
have demonstrated that the proliferation of vascular 
smooth muscle cells @MC) is a key step in the patho- 
genesis of atherosclerosis [l]. Although much attention 
has been focused an factors that stimulate SMC prolif- 
eration, very little is known about the mechanisms in- 
volved in maintaining SMCs in a quiescent growth state 
or re-establishing the normally quiescent growth state 
of SMCs following their proliferative response to inti- 
mal injury. 
Thrombin has central functions in hemostasis but has 
also been shown to elicit a wide range of cellular re- 
sponses, and multiple thrombin-mediated effects on 
vascular cells have been described, In cultured SMCs, 
ar-thrombin stimulates many growth-related signals, in- 
cluding activation of phospholipase C with generation 
of inositol triphosphate and increase in [Ca”],, stimula- 
tion of Na’/H* exchange and intracellular alkaliniza- 
tion or induction of the protooncogene, C-$X [2-4]. 
Thrombin exhibits direct mirogenic effect on neonatal 
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rat vascular SMC [2] and bovine aortic SMCs [S]. 
Whereas it is now recognbed that the enzymatically 
active form of a-thrombin is capable of initiating prolif- 
eration of quiescent fibroblasts [6,7], it was recently 
suggested that cl-thrombin was a potent mitogen for 
SMCs through a distinct non-enzymatic domain [S]. 
However, since Bar Shavit et al. [S] showed that throm- 
bin immobilized to a naturally produced extracellular 
matrix retained potent mitogenic activity toward SMCs, 
other authors have not been able to demonstrate hrom- 
bin-induced DNA synthesis or mitogenesis [8]. 
Recently, molecular cloning of a functional thrombin 
receptor on platelets and vascular endothelial cells re- 
vealed a novel proteolytic mechanism of receptor acti- 
vation [9,10]. These works revealed a new signalling 
mechanism in which a-thrombin cleaved its receptor’s 
amino-terminal extension to create a new receptor 
amino-terminus that functioned as a tethered ligand 
and activated the receptor. In these studies, a synthetic 
peptide of 14 residues (SFLLRNPNDKYEPF) (hereaf- 
ter refered to as thrombin agonist peptide: TRA) corre- 
sponding to the new receptor N-terminal was shown to 
activate the cloned thrombin receptor and induce plate- 
let activation. Since this ligand can only be generated by 
catalytic action of the enzyme, our work therefore con- 
sisted of studying the effect of this synthetic agonist 
peptide on the growth of vascular SMCs in culture. We 
also evaluated the activity of sulphated polysaccharides 
on thrombin- or the TRA-induced SMC proliferation. 
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2. MATERIALS AND METHODS 
2.1. Cltettticds 
Dulbecco’s modified Eagle medium (DMEM), fetal calf serum 
(FCS), glutamine, collagenase (type II), streptokinase and penicillin 
were purchased from Boehringer-Mannheim (France). Standard hep- 
arin (from porcine intestinal mucosa, I68 IUlmg) was from Sigma 
Chemicals Co. (France). Pentosan polysulphate (PPS), penlosan, N- 
desulpbated heparin, low molecular weight heparin (LMWH) (CY 
2 IB-Fraxiparin), No-(~-naphtyl~sulphonyl~~lycyl)~o~~~amidi~~ophen- 
ylalanyl-pipcridine (NAPAP) [I I] and the synthetic pptide 
(TRA)(SFLLRNPNDKYEPF) were from Sanofi Recherchc (Tou- 
louse, France). The heparin fraction with no affinity for anti.thrombin 
I11 (non-affine heparin) was a kind gift from J.C. Lormeau (Sanofi 
Rcchcrche, Gcntilly, France). Human a.thrombin (3,000 NIH Ulmg) 
was purchased from Centre Regional de Transfusion Sanguine (Stras- 
bourg. France). 
Smooth muscle cells (SMC) were isolated from the rabbit aorta as 
described previously [I?]. Briefly, media fragments from the thoracic 
aorta from New-Zealand rabbits (2.0-7.5 kg, Charles River, France) 
were incubated for 16 h at 37’C in DMEM containing collagenase 
(0. IS%), FCS (5%), penicillin (100 IU/ml), streptomycin (100 lug/ml) 
and glutamine (4 mM), After incubation, SMCs were sedimented by 
gentle centrifugation (400 x g, IO min), resuspended in DMEM + 10% 
FCS and grown at 37°C in a humidified atmosphere of 5% CO: in air. 
Culture medium (DMEM + 10% FCS) was changed every 3 days and 
a confluent SMC monolayer was obtained after about 7 days. Cells 
were routinely used from the third to the sixth passage. 
Cells were plated sparsely (lOI cells/well) in 96 well cluster plates 
(Nunc, Denmark) in DMEM + 0.5% FCS. After 3 days, cells in 
representative dishes were counted with a coulter counter (Coultron-. 
its, France) and fresh medium was added to the remaining dishes 
(DMEM + 0.5% FCS, cr.thrombin or TRA and the different conccn- 
trations of the drugs to be tested), For growth rate determinations, 
after 3 days in culture, cells were detached from triplicate wells by 
trypsin treatment (0.05% trypsin, O.O?% EDTA) and counted in a 
coulter counter. I&,, values were calculated on the basis of the linear 
regression lines established for each compound tested using a rcgres- 
sion program [171. 
3. RESULTS AND DISCUSSION 
3.1. Effects of cz-thrmbin and TRA on the proiiferarion 
of SMC in culture 
Addition of either native ct-thrombin or TRA to qui- 
eseiit rabbit aortic SMCs resulted in stimulation of 
their growth. As indicated in Fig. 1, both a-thrombin 
and TRA induced a 14-l&fold increase in cell number 
over a period of l-4 days. The concentration of a- 
thrombin required to get optimal cell proliferation 
(A,,,,) was 1 yM with a half-maximal response (ED,,) 
at 1 nM (Fig. 2). This observation is consistent with 
already published results [5]. The TRA, when tested at 
concentrations ranging from 0.1 nM to 10 ,uM, exhib- 
ited a significant mitogenic effect for SMCs, the A,,, as 
well as the EDSo of TRA being highly similar to those 
observed for native a-thrombin. 
Since the peptide we used has already been shown by 
Vu et al. [9] to mimick the new amino-terminus created 
by cleavage of the thrombin receptor, our results sug- 
gest that enzymatic activity of a-thrombin is necessary 
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Fig. 1. Time-course of SMC growth in the presence of cz-thrombin or 
TRA. Rabbit aortic S’MCs were seeded (10’ cells/well) in culture me- 
dium containing 0.5% FCS alone (A), 1 PM o-thrombin (0) or I PM 
TRA (m), Cells 4’trc trypsinized and counted at the indicated times. 
Data are reported as mean cell density ;t S.D. horn 3 replicate cultures. 
for the triggering of its mitogenic effect on SMCs. 
Hence, our results create a discrepancy with those of 
Bar Shavit et al. who recently suggested that a-throm- 
bin was a potent mitogen for vascular SMCs through 
a distinct non-enzymatic domain [S]. In order to con- 
firm our hypothesis, the specificity of thrombin-induced 
proliferation was demonstrated by growing SMCs in 
the presence of NAPAP. This direct thrombin inhibitor 
[ 1 l] did not affect the mitogenic effect of FCS or TRA 
but blocked the a-thrombin-induced proliferation of 
SMCs with an I& value (concentration which inhibits 
50% of cell growth) of 0.35 1 0.04pM (n = 3) (Fig. 3). 
At this concentration, NAPAP exhibited a -60% inhibi- 
tion of the amidolytic activity of a-thrombin, a 100% 
inhibitory effect being attained after incubation of a- 
thrombin with 1 ,uM of NAPAP. Therefore, all of our 
observations indicate that a-thrombin functions as a 
potent mitogen toward vascular SMCs through its cnta- 
lytic activity. 
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Fig. 2. ProGfcrstisr effects of z-thrombin and TRA on SMC. Sparse 
cultures of SMCs (IO’ cells/well) were grown in DMEM + 0.5% FCS 
with the indicated concentrations ofa-thrombin (0) or TRA (m). After 
3 dnys in culture, cells were trypsinized and counted. Data arc reported 
as mean cell density = S.D. from 3 replicate cultures. 
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Fig. 3. Effect of NAPAP on SMC growth. SMCs (1O’cellslwellj were 
allowed to grow in the presence of DMEM + 0.5% FCS supplemented 
with a-thrombin (I PM)(O), TRA (I yM) (ml or 5% FCS (A). Increas- 
ing concentrations of NAPAP were added simultaneously. After 3 
days in culture, triplicate wells were trypsinized and cells were 
counted. In the controls, cell numbers were (cells/well): thrombin 
13,500 ?: 700, TRA 15,900 k 1,000, FCS 14,300 + 550, Data are 
expressed as mean % inhibition of proliferation compared with repii- 
cate cultures grown without the inhibitor (I! = 3). 
3.2. Effect of Itepmin ad related corttpomds on tt- 
In recent years, glycosaminoglycans, such as heparin, 
have been shown to be potent inhibitors of the prolifer- 
ation of vascular SMCs in culture and in vivo [12-141. 
Indeed, in the blood vessel wall, heparan sulphate may 
play a role in the regulation of cell proliferation, since 
endothelial cells, but also SMC themselves, produce 
heparan sulphate with high anti-proliferative activity 
for SMC [15,16]. We therefore valuated the effect of 
heparin on thrombin. or TRA-induced SMC growth. 
When different concentrations of standard heparin were 
added to sparse cultures of SMCs in combination with 
TRA, a strong anti-proliferative ffect was observed 
(Fig. 4). Standard heparin, at a concentration as low as 
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Fig, 4. Effect of standard heparin on SMC growth. SMCs (IO3 cells/ 
well) were allowed to grow in the presence of DMEM + 05% FCS 
supplemented with a-thrombin (I yM) (o), TRA (I PM) (m) or 5% 
FCS (A). Increasing concentrations of standard heparin were added 
simultaneously. After 3 days in cuhurc. triplicate wells were trypsi- 
niized and cells were counted. Cell number in tke controls were the 
same as that determined in Fig. 3. Data arc expressed as mean % 
inhibition of proliferation compared with replicate cultures grown 
without heparin (n = 3). 
Table I 
Comparative inhibitory efl’ects of various sulphated polysaccharides 
on serum- and TRAminduced SMC growth 
Compounds 
Standard hcparin 
Low mol. wt. heparin 
Non-affine heparin 
N-Desulphated hcparin 
Pcntosan polysulphatc 
Pcmosan 
-. 
ICs W&ml) 
FCS TRA 
250 +- 13 32 “, 4.S 
465 5 31 312 r 27 
280 + 29 282 3 
5 500 z+ 500 
412 9 6t I 
> 500 =. SW 
SMCs were allowed to grow in the presence of TRA (I PM) or 5% 
FCS. Increasing concentrations of the various compounds were added 
simultaneously. After 3 days in culture, triplicate wells were trypsi- 
nized and cells were counted. Data arc cxprcssed as means + S.D. 
(0 = 3), 
10 pg/ml, significantly reduced the proliferative re- 
sponse to an optimal concentration of TRA (1 PM), the 
I& value being 32 + 4.5 @/mi. Under the same exper- 
imental conditions, even at high concentrations, tand- 
ard heparin did not affect the a-thrombin-stimulated 
SMC growth, whereas, when added in combination 
with 5% FCS, standard heparin reduced SMC growth 
with an lC& value of 250 + 13 pg/rnl. This latter figure 
is in agreement with already published results [12]. The 
fact that TRA induced SMC growth without altering 
thrombin mitogenic response may indicate that heparin 
interacts directly with TRA, but further characteriza- 
tion of the binding properties of TRA to SMCs will be 
necessary to resolve this issue. 
As indicated in Table I, heparin, which showed no 
affinity for anti-thrombin III, exhibited almost the same 
effect as standard heparin on both TRA- and FCS- 
induced proliferation of SMCs. Therefore, as already 
shown in vivo or with respect o, the mitogenic effect of 
FCS [ 13,141, our observations indicate that the effect of 
heparin on the mitogenic activity of TRA is not related 
to its anti-coagulant activity. Molecular mass and 
global charge of the molecule appeared to be important 
for the anti-proliferative effect of heparin since decrease 
in the mean molecular weight (from 12.5 kDa for stand- 
ard heparin to 4.7 kDa for the low molecular weight 
heparin fraction) or N-desulphation of standard hepa- 
rin resulted in a strong loss of its anti-proliferative effect 
with regard to both mitogens. 
Since pentosan polysulphate (PPS) has been de- 
scribed as a potent inhibitor or SMC proliferation [12], 
we investigated it for its ability to reduce TRA-induced 
SMC proliferation. In our experimental conditions. PPS 
exhibited a 5-fold higher anti-proliferative ffect than 
standard heparin and showed no effect on the mitogenic 
effect of native thrombin. Such an activity has already 
been reported with regard to FCS-induced SMC growth 
[12]. As already observed for heparin, pentosan was 
devoid of any effect, showing that the anti-proliferative 
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activity of PPS was highly dependent on the charge of [6] Chen, L.B. and Buchanan, J.M. (1975) Proc. Nat]. Acad. Sci. 
the molecule. USA 72, 131-135. 
In summary, the present study demonstrates that en- 
zymatic activity of cr-thrombin is necessary for its mitoh 
genie activity with regard to SMCs. Furthermore, our 
work reports for the first time the mitogenic effect of a 
peptide mimicking the amino-terminus created by enzy- 
matic cleavage of the thrombin receptor. We also fo- 
cused on the effect of heparin and related molecules on 
this mitogenic effect and work is now underway to de- 
termine if these effects may be considered part of their 
mechanism of action on SMC proliferation. 
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